Table 3.

MTOPS Versus CombAT

Design	MTOPS	CombAT
Placebo control	Yes	No
Selection criteria for	No	Yes
large prostates (> 30 cm3)
Primary endpoint	Clinical BPH progression	AUR and BPH invasive
		intervention
Funding	National Institutes of Health	GlaxoSmithKline

AUR, acute urinary retention; BPH, benign prostatic hyperplasia; CombAT, Combination of Avodart and Tamsulosin; MTOPS, Medical Therapy of Prostatic Symptoms.